Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | THPO | P40225 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11256608 | 0.84 | KMO (1.00) | KMONOS1NOS3NOS2LMNA | |
| Bromchlorenone SCHEMBL637478 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL6164657 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL5536706 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL1115840 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL5536703 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| Bromchlorenone SCHEMBL9772032 | 0.76 | KMO (0.70) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL5634658 | 0.76 | KMO (0.64) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL30295627 | 0.75 | KMO (0.68) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL11045421 | 0.74 | KMO (0.72) | KMONOS1NOS3NOS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | TRINUERO (KR) | 2022-01-20 | — | — | US | claimed |
| EP-4205741-B1 | CYP2E1 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY-MEDIATED DISEASES | SUZHOU LINGXI BIOTECHNOLOGY CO LTD (CN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4609911-A2 | COMPOUNDS EFFECTIVE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES AND USES THEREOF | Sinew Pharma Inc. (TW) | 2025-09-03 | — | — | EP | disclosed |
| EP-3991724-B1 | MANNITOL FOR USE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES | SINEW PHARMA INC (TW) | 2025-07-16 | — | — | EP | disclosed |
| US-20240335404-A1 | SUBSTITUTED ESTERS CONTAINING POLYOLS AND SACCHARIDES FOR TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES | SINEW PHARMA INC. (TW) | 2024-10-10 | — | — | US | disclosed |
| US-12083088-B2 | Substituted esters containing polyols and saccharides for treating hepatotoxicity and fatty liver diseases | SINEW PHARMA INC. (TW) | 2024-09-10 | — | — | US | disclosed |
| EP-3846938-B1 | IMMOBILIZED ENZYMES AND MICROSOMES ON MAGNETIC SCAFFOLDS | ZYMTRONIX CATALYTIC SYSTEMS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-4205741-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| EP-4173619-A2 | NEW ACETAMINOPHEN COMPOUND COMPOSITION WITHOUT SIDE EFFECT TO LIVER | National Defense Education and Research Foundation (TW) | 2023-05-03 | — | — | EP | disclosed |
| WO-2001011035-A1 | MONOCLONAL ANTIBODIES FOR HUMAN CYTOCHROME P450 3A4 AND HUMAN CYTOCHROME P450 2C9 | MERCK & CO., INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-1011708-A1 | ANTI-PEPTIDE ANTIBODY AGAINST HUMAN CYTOCHROME P450 3A4 | Merck & Co., Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1007034-A1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| US-5939530-A | MONOCLONAL ANTIBODIES AGAINST SPECIFIC CYTOCHROMES; USEFUL IN ANALYSIS OF TOXICITY OF ENVIRONMENTAL CHEMICALS, CARCINOGENS; ANALYSIS OF MODES OF ACTION OF ANTIBIOTICS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-08-17 | — | — | US | disclosed |
| US-5886157-A | EXTRACTING THE PROTEIN FROM MEMBRANE CELLS WITH NONIONIC DETERGENT, CENTRIFUGING, PURIFYING THROUGH CHROMATOGRAPHIC COLUMN | VANDERBILT UNIVERSITY (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1999008676-A1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998044939-A1 | ANTI-PEPTIDE ANTIBODY AGAINST HUMAN CYTOCHROME P450 3A4 | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| EP-0861268-A1 | INHIBITORY AND NON-INHIBITORY ANTIGEN BINDING POLYPEPTIDES AGAINST HUMAN P450 ENZYMES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997019112-A1 | INHIBITORY AND NON-INHIBITORY ANTIGEN BINDING POLYPEPTIDES AGAINST HUMAN P450 ENZYMES | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335404-A1 | SUBSTITUTED ESTERS CONTAINING POLYOLS AND SACCHARIDES FOR TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES | CPT1A, UGCG, UGGT1 | KMO 1322/4885NOS1 2139/4885NOS3 1873/4885 |
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | CYP2E1, CYP11B1, CYP27A1 | KMO 613/4885NOS1 478/4885NOS3 794/4885 |
| US-12083088-B2 | Substituted esters containing polyols and saccharides for treating hepatotoxicity and fatty liver diseases | CPT1A, UGCG, UGGT1 | KMO 1322/4885NOS1 2139/4885NOS3 1873/4885 |
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | KEAP1, SLC5A1, GCLC | KMO 705/4885NOS1 752/4885NOS3 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.